Response to Comments: MolDX: Envisia, Veracyte, Idiopathic Pulmonary Fibrosis Diagnostic Test

This is an administrative Response to Comments notice for the MolDX Envisia/Veracyte idiopathic pulmonary fibrosis diagnostic test that documents the comment period (10/04/2018–12/14/2018), notice period (04/11/2019–05/26/2019), and the LCD finalization date (05/27/2019). The document does not contain clinical coverage criteria, limitations, frequency limits, or required claim documentation.

"This document records administrative dates: comment period 10/04/2018–12/14/2018; notice period 04/11/2019–05/26/2019; LCD becomes final 05/27/2019. No clinical coverage criteria or required claim ..."

Sign up to see full coverage criteria, indications, and limitations.